DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
NYSE:DBD - New York Stock Exchange, Inc. - US2536512021 - Common Stock - Currency: USD
DBD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 32 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has an average financial health and profitability rating. DBD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year DBD was profitable.
DBD had a positive operating cash flow in the past year.
In the past 5 years DBD reported 4 times negative net income.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
DBD has a Return On Assets (-0.28%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -1.04%, DBD is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
With a decent Return On Invested Capital value of 9.30%, DBD is doing good in the industry, outperforming 65.63% of the companies in the same industry.
DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 16.44%.
The last Return On Invested Capital (9.30%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.28% | ||
| ROE | -1.04% | ||
| ROIC | 9.3% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
With a decent Operating Margin value of 7.46%, DBD is doing good in the industry, outperforming 68.75% of the companies in the same industry.
In the last couple of years the Operating Margin of DBD has grown nicely.
The Gross Margin of DBD (25.30%) is worse than 62.50% of its industry peers.
DBD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.46% | ||
| PM (TTM) | N/A | ||
| GM | 25.3% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
Compared to 1 year ago, DBD has about the same amount of shares outstanding.
The number of shares outstanding for DBD has been reduced compared to 5 years ago.
DBD has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 1.83 indicates that DBD is not a great score, but indicates only limited risk for bankruptcy at the moment.
DBD has a Altman-Z score (1.83) which is in line with its industry peers.
DBD has a debt to FCF ratio of 5.47. This is a neutral value as DBD would need 5.47 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.47, DBD is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
DBD has a Debt/Equity ratio of 0.94. This is a neutral value indicating DBD is somewhat dependend on debt financing.
DBD has a Debt to Equity ratio of 0.94. This is in the lower half of the industry: DBD underperforms 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 5.47 | ||
| Altman-Z | 1.83 |
ROIC/WACC0.96
WACC9.66%
2.3 Liquidity
A Current Ratio of 1.35 indicates that DBD should not have too much problems paying its short term obligations.
The Current ratio of DBD (1.35) is comparable to the rest of the industry.
A Quick Ratio of 0.91 indicates that DBD may have some problems paying its short term obligations.
With a Quick ratio value of 0.91, DBD perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.91 |
3. Growth
3.1 Past
DBD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.82%, which is quite impressive.
The Earnings Per Share has been growing by 69.69% on average over the past years. This is a very strong growth
Looking at the last year, DBD shows a decrease in Revenue. The Revenue has decreased by -2.66% in the last year.
The Revenue has been decreasing by -3.18% on average over the past years.
EPS 1Y (TTM)88.82%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-68.91%
Revenue 1Y (TTM)-2.66%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-6.06%
3.2 Future
Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.73% on average per year.
DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.37% yearly.
EPS Next Y-8.16%
EPS Next 2Y10.15%
EPS Next 3Y9.73%
EPS Next 5YN/A
Revenue Next Year1.03%
Revenue Next 2Y1.49%
Revenue Next 3Y2.37%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.35, which indicates a correct valuation of DBD.
DBD's Price/Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 68.75% of the companies in the same industry.
When comparing the Price/Earnings ratio of DBD to the average of the S&P500 Index (26.31), we can say DBD is valued slightly cheaper.
With a Price/Forward Earnings ratio of 10.61, the valuation of DBD can be described as very reasonable.
Based on the Price/Forward Earnings ratio, DBD is valued a bit cheaper than 68.75% of the companies in the same industry.
DBD is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.06, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.35 | ||
| Fwd PE | 10.61 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DBD is valued cheaper than 100.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 90.63% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.91 | ||
| EV/EBITDA | 6.02 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.15%
EPS Next 3Y9.73%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
49.71
+0.29 (+0.59%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.7%
Inst Owner Change2.76%
Ins Owners1.65%
Ins Owner Change2.94%
Market Cap1.85B
Analysts82.86
Price Target73.78 (48.42%)
Short Float %2.68%
Short Ratio6.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.58%
Min EPS beat(2)-8.92%
Max EPS beat(2)1.76%
EPS beat(4)2
Avg EPS beat(4)-12.72%
Min EPS beat(4)-52.17%
Max EPS beat(4)8.44%
EPS beat(8)5
Avg EPS beat(8)24.37%
EPS beat(12)7
Avg EPS beat(12)-62.7%
EPS beat(16)7
Avg EPS beat(16)-98.89%
Revenue beat(2)0
Avg Revenue beat(2)-1.11%
Min Revenue beat(2)-1.34%
Max Revenue beat(2)-0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)1.85%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)3
Avg Revenue beat(12)-1.61%
Revenue beat(16)3
Avg Revenue beat(16)-2.7%
PT rev (1m)0%
PT rev (3m)15.73%
EPS NQ rev (1m)-19.73%
EPS NQ rev (3m)-21.17%
EPS NY rev (1m)-8.79%
EPS NY rev (3m)-22.77%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)-0.3%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.35 | ||
| Fwd PE | 10.61 | ||
| P/S | 0.5 | ||
| P/FCF | 10.91 | ||
| P/OCF | 9.83 | ||
| P/B | 1.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.02 |
EPS(TTM)3.04
EY6.12%
EPS(NY)4.68
Fwd EY9.42%
FCF(TTM)4.56
FCFY9.17%
OCF(TTM)5.06
OCFY10.17%
SpS99.22
BVpS26.41
TBVpS-10.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.28% | ||
| ROE | -1.04% | ||
| ROCE | 11.77% | ||
| ROIC | 9.3% | ||
| ROICexc | 10.74% | ||
| ROICexgc | 34.04% | ||
| OM | 7.46% | ||
| PM (TTM) | N/A | ||
| GM | 25.3% | ||
| FCFM | 4.59% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexcg growth 3Y-11.73%
ROICexcg growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score5
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 5.47 | ||
| Debt/EBITDA | 2.27 | ||
| Cap/Depr | 14% | ||
| Cap/Sales | 0.5% | ||
| Interest Coverage | 2.11 | ||
| Cash Conversion | 46.12% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z | 1.83 |
F-Score5
WACC9.66%
ROIC/WACC0.96
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.82%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-68.91%
EPS Next Y-8.16%
EPS Next 2Y10.15%
EPS Next 3Y9.73%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.66%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%-6.06%
Revenue Next Year1.03%
Revenue Next 2Y1.49%
Revenue Next 3Y2.37%
Revenue Next 5YN/A
EBIT growth 1Y39.83%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.02%
EBIT Next 3Y13.05%
EBIT Next 5YN/A
FCF growth 1Y160.17%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y173.57%
OCF growth 3Y6.68%
OCF growth 5Y26.59%